Introduction
============

Ecstasy is a commonly abused drug worldwide for its stimulating, pro-social and euphoric effects ([@B21]). The active ingredient of ecstasy is 3,4-methylenedioximethamphetamine (MDMA) that acutely releases noradrenaline, serotonin, and dopamine in synaptic clefts ([@B21]; [@B35]). Besides of its initial rewarding effects, the drug can lead to lasting functional consequences: elevated risk of mood disorders and persistent cognitive disturbances were demonstrated in multiple animal and human studies ([@B34]; [@B21]; [@B10]; [@B26]; [@B33]). A central region of cognitive functions, particularly memory, is the hippocampus (HC) ([@B43]). Its anatomical structure, in terms of organization of neuronal circuitries and (micro)vasculature makes it especially vulnerable to various homeostatic challenges ([@B42]). The HC seems to be the most vulnerable brain region also to the toxic effects of MDMA in rats and, with some suggestive evidence, in humans ([@B5], [@B4]; [@B15]; [@B39]). MDMA-induced hyperthermia, free radical production, relative ischemia through disruption of cerebral autoregulation ([@B14]; [@B21]; [@B18]; [@B12]) and lasting selective serotonergic toxicity ([@B27]; [@B12]; [@B4], [@B3]; [@B6]) are all mechanisms that could contribute to the damage of HC. Translation of these complex pathophysiological processes to molecular mechanisms leading to the damage of the HC and to impairments of learning and memory processes are, however, less explored, although changes in LTP in hippocampal slices after neurotoxic MDMA treatment have been described earlier ([@B31]). We have demonstrated previously that mRNA levels of key members of the long-term potentiation (LTP) pathway were downregulated in the HC 3-weeks after MDMA administration, in parallel with decreased expression of memory and cognition gene sets ([@B39]). These may be important contributors to MDMA-induced cognitive impairments. However, based on the complexity of the pathophysiological processes mentioned above, further molecular mechanisms are presumed to contribute. These probably employ downstream mediators, like transcription factors, which regulate expression of mRNA and protein levels directly, and link initial alterations with long-term consequences. Nevertheless, transcription factors remained uninvestigated after chronic MDMA administration.

In the present study, we have analyzed our previously obtained data, measured by Illumina whole-genome beadarrays, with gene-set enrichment analysis (GSEA) using the MSigDB transcription factor sets, to identify transcription factors that may be responsible for the long-term cognitive impairments in the vulnerable HC region 3-weeks after a single-dose MDMA administration.

Materials and Methods {#s1}
=====================

For detailed methods see ([@B39]). Briefly, 21 approximately 8 weeks old male Dark Agouti (DA) rats (Harlan, Olac Ltd., Shaw's Farm, Blackthorn, Bicester, United Kingdom) weighing 152 ± 3,58 g (SEM) were used. After random assignment, MDMA \[(±)3,4-methylenedioxymethamphetamine (Sanofi-Synthelabo-Chinoin, Hungary, purity \>99.5%)\] dissolved in 0.9% NaCl (SAL), at an equivalent dose of 15 mg/kg free base, or SAL (for control animals) was administered intraperitoneally in a volume of 1 ml/kg. Three weeks after injections rats were sacrificed and HC regions dissected (dorsal HC: from bregma -2.5 to -4.5 mm). RNA extraction was performed according to the TRIzol method ([@B45]; [@B38]). Samples with lowest RNA concentrations were excluded until both MDMA and control groups consisted of eight animals. Randomly selected samples were pooled by two and sent to Service XS (Leiden, Netherlands) for microarray analysis with the Illumina (San Diego, CA, United States) RatRef-12v1 beadarray expression chip. Raw data were analyzed using quantile normalization with beadarray, preprocessCore and puma Bioconductor packages for R ([@B20]; [@B16]; [@B36]; [@B40]). These methods created the minimum probability of positive log ratio (MinPplr), a statistical significance value. A gene was considered significant, if MinPplr was below 0.001 \[to correct for multiple hypothesis testing ([@B9]; [@B37])\]. Results were validated with rt-PCR (for result see [@B39]) and microarray data uploaded in Gene Expression Omnibus ([@B17]) under GSE47541^[1](#fn01){ref-type="fn"}^. GSEA was performed using GSEA software from the Broad Institute at MIT^[2](#fn02){ref-type="fn"}^. GSEA uses a ranked list of all examined genes and searches for groups of genes (gene sets) that are enriched (overrepresented/underrepresented) in the top/bottom of this list. We used official MSigDB C3 TFT (transcription factor) gene sets for grouping, which classifies genes based on shared regulatory motifs and, hence, represents common transcription factor binding properties. Accordingly, up/downregulation of a given set in GSEA means that genes regulated by a given factor are up/downregulated. Sets containing more than 500/less than 15 genes were excluded, *t*-test was used for ranking and gene set was chosen as permutation type. Thousand permutations were made with seed of permutation set to 149. Normalized enrichment scores (NES), representing relative enrichment in a given phenotype, nominal *p*-values and false discovery rates (FDR) were calculated. A gene set was considered significant with FDR *q*-value below 0.05 ([@B9]). GSEA calculates results obtained through analysis of every (both significant/non-significant) genes between two groups (in this case MDMA vs. SAL). However, we were also interested in sets that may contain most of the significantly altered genes. Therefore, the number of significantly altered genes (MinPplr \< 0.001) was counted in each significant (FDR \< 0.05) gene set to identify those transcription factors that may be largest contributors to the most substantial changes in the HC 3 weeks after administration.

All experiments complied with the European Community Council Directive of 24 November 1986 (86/609/EEC), National Institutes of Health Principles of Laboratory Animal Care (NIH Publication 85-23, revised 1985) and national laws (the Hungarian Governmental Regulation on animal studies, 31 December 1998 Act) and were approved by the National Scientific Ethical Committee on Animal Experimentation and permitted by the Food Chain Safety and Animal Health Directorate of the Central Agricultural Office, Hungary (permission number: 22.1/3152/001/2007).

Results
=======

Gene-set enrichment analysis revealed 14 gene sets that were dysregulated with an FDR *q*-value below 0.05 3 weeks after a single-dose MDMA treatment in the HC compared to the controls (Table [1](#T1){ref-type="table"}). Among the gene sets one was upregulated, the other 13 were downregulated with the largest downregulation of the Pax4 set (the only upregulated set possesses no known binding factor). From the 14 dysregulated gene sets three bind forkhead box (Fox) transcription factors, namely FoxO1, FoxO4, and FoxJ1, others could not be grouped into families.

###### 

Up- and downregulated transcription factor gene sets 3 weeks after a single-dose MDMA treatment in the hippocampus of Dark Agouti rats.

  Name of the gene set      Presumed transcription factor able to bind to regulatory motif   NES          FDR *q*-value
  ------------------------- ---------------------------------------------------------------- ------------ ---------------
  ACTWSNACTNY_UNKNOWN       Unknown                                                          1.936839     0.022079093
  V\$VDR_Q6                 Vitamin D receptor                                               -1.7801763   0.047251813
  AACWWCAANK_UNKNOWN        Unknown                                                          -1.8135455   0.03694073
  V\$FOXO4_01               FoxO4                                                            -1.8182034   0.038588446
  GTGGGTGK_UNKNOWN          Unknown                                                          -1.8234655   0.039833214
  V\$AP3_Q6                 Currently unknown                                                -1.8274099   0.042258345
  V\$SP3_Q3                 Sp3                                                              -1.8449765   0.03698938
  V\$COREBINDINGFACTOR_Q6   Core-binding factor                                              -1.8531265   0.038751207
  V\$OCT1_03                Oct1 (Pou2f1)                                                    -1.8553681   0.04364336
  V\$FOXO1_01               FoxO1                                                            -1.8712838   0.042675186
  V\$FOXJ2_02               FoxJ2                                                            -1.8762817   0.049202178
  YRCCAKNNGNCGC_UNKNOWN     Unknown                                                          -1.9217957   0.037266485
  V\$PITX2_Q2               Pitx2                                                            -1.9697808   0.025443465
  V\$PAX4_04                Pax4                                                             -2.1240275   0.0034508866
                                                                                                          

According to the gene set enrichment analysis, altogether 14 gene sets were dysregulated (1 up- and 13 downregulated, marked with red and blue, respectively) with a false discovery rate (FDR) below 0.05. All of the significant sets are shown here in descending order, according to their nominal enrichment scores (NES), thus, toward lower expression of their respective genes. Table contains the most probable transcription factors that may bind regulatory motifs. Those genes, that were annotated to a set based only on common regulatory motifs, but unknown transcription factors are marked as "unknown" in their respective columns (four sets). AP3 set currently lacks associated transcription factor.

To reveal gene sets with the highest number of altered genes, we counted significant gene entries (MinPplr \< 0.001) in each significant set (FDR \< 0.05). Results showed that AP3 regulated gene set contained the most significantly altered genes with 17 entries, \[but AP3 is currently not associated with known transcription factor (see section "Discussion")\], followed by vitamin D receptor (VDR) regulated set with 15 entries. Results with the significant genes are shown in Table [2](#T2){ref-type="table"}.

###### 

Number of genes with significantly altered expression 3 weeks after MDMA treatment in the hippocampus in the significantly altered transcription factor gene sets.

  Gene set                   Number of sign. Genes              Genes                                                                                                                                  
  -------------------------- ----------------------- ---------- --------- --------- -------- -------- ---------- -------- -------- -------- -------- ------- -------- -------- ------- -------- ------ -------
  V\$AP3_Q6                  17                      PPM1E      CRK       SEPHS2    ADCY8    DDX6     PLAG1      TRPS1    CDH8     SCA2     IGF2     NTRK2   CDH9     MPP6     CXXC4   SLC5A3   RORA   NTRK3
  V\$VDR_Q6                  15                      CEBPB      CD3E      CAMK2N2   KLF1     PMP22    PABPC1     ATP2B3   GRIA3    SLC4A4   NTRK2    RBBP6   LPHN1    DNMT3A   TNR     GRIN2A          
  V\$PITX2_Q2                12                      DCTN4      SEMA5B    LPHN2     TRPS1    LRP6     PRICKLE2   NTRK2    DP1      GSK3B    RORA     BMPR2   NFIX                                      
  V\$SP3_Q3                  12                      DNAJB5     BAI2      KLF1      SH3BP5   PABPC1   KDELR1     PLAG1    ENH      ASCL1    DNMT3A   GSK3B   GRIN2A                                    
  V\$PAX4_04                 11                      RFX3       UBE2B     PLAG1     GRIA3    NTRK2    TCF4       GNAO     GSK3B    SLC5A3   TNR      NFIX                                              
  V\$FOXO4_01                11                      KLF1       ZHX2      SH3BP5    ITGA1    LPHN2    PLAG1      TRPS1    SLC4A4   ENPP2    LPHN1    NTRK3                                             
  V\$FOXO1_01                11                      CAMK2N2    KLF1      SH3BP5    IGSF1    LPHN2    PLAG1      PLXDC2   POU3F2   MGLL     NTRK3    NFIX                                              
  GTGGGTGK_UN-KNOWN          11                      NCK2       KLF1      ZHX2      ACVR1C   ATP2B3   MYCL1      BASP1    IGF2     DLGAP4   KCND2    CDH22                                             
  V\$OCT1_03                 9                       KLF1       PRKG1     AMD1      PLAG1    TCF4     DLGAP4     GDA      CDH22    NFIX                                                                
  V\$FOXJ2_02                9                       GNAZ       ADAM23    ACVR1C    NFIA     CDH9     TCF4       RORA     BMPR2    NFIX                                                                
  AACWWCAANK_UNKNOWN         8                       RCN3       RPS6KA5   LPHN2     PLAG1    IGF2     ALCAM      PCDH17   BMPR2                                                                        
  V\$COREBINDING-FACTOR_Q6   6                       MAFG       ENPP1     ENPP2     GSK3B    BMPR2    NFIX                                                                                             
  ACTWSNACTNY_UNKNOWN        5                       SLC9A3R1   NRAP      RCN3      TRPS1    MPP6                                                                                                      
  YRCCAKNNGNCGC_UNKNOWN      3                       BAI2       MYCL1     GRIN2A                                                                                                                       
                                                                                                                                                                                                       

The table enlists names of genes that were significantly up/downregulated (MinPplr \< 0.001) in the gene expression analysis and belonged to one of the significantly altered transcription factor gene sets 3 weeks after single-dose MDMA treatment in rat hippocampi. Results show that AP3 transcription factor regulated genes are most prominent while vitamin D receptor gene set also contained 15 genes from the significantly altered ones. Red genes represent those that were significantly (MinPplr \< 0.001) upregulated, while blue ones were downregulated. Genes are represented by their respective official symbols.

Discussion
==========

The present study shows that gene expression alterations 3 weeks after a single-dose MDMA treatment in the HC are probably mediated by 14 different transcription factors, among them hypoxia/ischemia-induced members of the FoxO family, Sp3 and Pax4. The AP3 regulated set contained the most significantly dysregulated genes, but lacks associated transcription factor, while the VDR gene set contained the second most entries. These results suggest that etiologically hypoxia/ischemia may be an important factor in the vulnerability of the HC and vitamin D supplementation may be tested to compensate for the most substantial cognitive effects of the drug.

Among transcription factors regulating the significantly altered sets several could be related to hypoxia/ischemia, a known consequence of MDMA administration ([@B18]). For example, the Pax4 regulated gene set was downregulated after transient hypoxic condition in the fetal pituitary of sheep ([@B50]). FoxO1 and FoxO4 were implicated in antioxidant mechanisms after brain ischemia ([@B1]; [@B19]; [@B8]; [@B24]). Polymorphisms in Pitx2 associated consistently with ischemic stroke in genome-wide association studies \[[@B46]; [@B30]; [@B32]\]. Significantly decreased Sp3 protein levels were revealed after 7 days of hypobaric hypoxia in HC of rats ([@B23]). Other transcription factors had wide-scale roles in different processes, e.g., FoxJ2 is an important regulator of dopaminergic neurons ([@B48]) and Oct1 (Pou2f1) polymorphisms associated with Alzheimer's disease ([@B44]). Core-binding factor is a large complex from Runx1-3 and core-binding factor B, which possesses important transcriptional regulatory properties, and Runx1 was induced after traumatic brain injury ([@B29]). From the dysregulated gene sets in four, including the only upregulated one, genes are annotated only by common regulatory motifs that are not associated with known transcription factors, indicating that so far unidentified regulatory elements may also contribute to the long-term effects of MDMA. In sum, our results suggest that MDMA employs FoxO1/4, Pitx2, Sp3, and Pax4-dependent mechanisms after its initial vasoactive monoamine release and consequent ischemia/hypoxia and changes in these transcription factors may be responsible for the long-lasting influence on HC processes and the often observed cognitive impairments.

From this aspect, perhaps the most interesting result is that most of the VDR regulated genes were downregulated (see Table [2](#T2){ref-type="table"}). In fact, the second highest number of genes with significantly altered expressions were among the VDR regulated genes, including those involved in LTP, like upregulated calcium/calmodulin-dependent kinase inhibitor *Camk2n2* and downregulated glutamate receptors NMDA2A (*Grin2a*) and AMPA3 (*Gria3*). While some of the other transcriptional regulators may also influence genes important for regulation of LTP, none of them offer such straightforward intervention as VDR regulated one in the form of vitamin D supplementation. This is especially tempting for multiple reasons. First, vitamin D exerts its effects via VDR, which after activation binds directly to DNA and influences gene transcription ([@B47]; [@B22]; [@B7]). Vitamin D was demonstrated to counteract consequences of hypoxia/ischemia via VDR ([@B49]), showed neuroprotective effects in hippocampal neurons after hypoxic insult ([@B25]), could influence LTP ([@B41]), enhanced cognitive performance in dementia ([@B28]), and protected from the serotonin-depleting effects of methamphetamine, a close relative of MDMA ([@B13]). Furthermore, a transient decrease in plasma calcitriol level was demonstrated in humans by a metabolomic analysis after acute MDMA administration ([@B11]) and ecstasy users promote the use of vitamin D in user-to-user posts^[3](#fn03){ref-type="fn"}^. However, no previous studies investigated vitamin D effects after MDMA use (in PubMed no hit with "MDMA" and "vitamin D" MeSH terms, retrieved on 11th of August, 2018). Harm-reduction techniques, found overall on the internet, target known acute actions of MDMA and suggest application of antioxidants, hydration, and cooling to attenuate the negative effects. Among those cooling was extensively studied and showed limited success (see e.g., [@B2]). Nevertheless, based on our results, vitamin D might have the potential to compensate for some of the long-term consequences of MDMA in the highly vulnerable HC.

Conclusion
==========

While our study has to be interpreted with caution due to the indirect examination of the transcription factors and the exclusive investigation of the HC, it provides evidence for an important role of ischemia and subsequent FoxO1/4, Pitx2, Sp3, and Pax4-dependent mechanisms in MDMA-induced hippocampal impairments. In addition, it also raises the possibility of a better, simple, and precision-medicine based harm reduction technique with vitamin D to compensate for the cognitive deficits of the drug.
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